Lv3
340 积分 2023-02-28 加入
Role of (−)-epigallocatechin-3-gallate in cell viability, lipogenesis, and retinol-binding protein 4 expression in adipocytes
12小时前
已完结
Retinol-binding protein 4 and peroxisome proliferator-activated receptor-γ in steatotic liver transplantation
12小时前
已完结
O-GlcNAcylation promotes the progression of nonalcoholic fatty liver disease by upregulating the expression and function of CD36
2天前
已完结
Mitochondrial damage-associated molecular patterns (mito-DAMPs): determinants of hepatopathy progression and therapeutic implications
4天前
已完结
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
7天前
已完结
Health-Related quality of life (HRQL) assessments in a 52-Week, Double-Blind, randomized, Placebo-Controlled phase 3 study of resmetirom (MGL-3196) in patients with metabolic dysfunction associated steatohepatitis (MASH) and fibrosis
7天前
已完结
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial
7天前
已完结
Multi-omics analysis of hepatic outcomes in T2DM-MAFLD patients treated with semaglutide: a single-centre, longitudinal, data-driven study
7天前
已完结
Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity
10天前
已完结
Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis
10天前
已完结
皖公网安备34019202002308
